Our story began in 1994
Symyx Technologies was founded to discover new materials for the chemical, electronics and life science industries
Symyx put its screening technology to use for pharmaceutical research. With its proprietary technology, Symyx was able to generate hundreds to thousands of unique materials at a time and screen them rapidly and automatically for desired properties. In addition to producing catalysts for the manufacture of pharmaceuticals, chemicals and plastics, it created polymers that could be used as medicines.
Symyx Technologies spun out its proprietary polymer drug discovery and development platform into a separate privately-held company called Ilypsa
Ilypsa was focused on developing non-absorbed polymer medicines for kidney disease. Its lead investigational medicine was for hyperphosphatemia, or abnormally high levels of phosphate in the blood, which is common in people receiving kidney dialysis for chronic kidney disease (CKD).
Amgen acquired Ilypsa
Amgen focused on developing the lead investigational polymer medicine for hyperphosphatemia. Astellas, which had licensed rights to the medicine, currently markets it in Japan.
Relypsa was founded
Former Illypsa executives spun out the proprietary polymer drug discovery and development technology from Amgen, including the hyperkalemia program, and created Relypsa.
Relypsa became a Vifor Pharma company
Today, Relypsa is focused on the development and commercialization of late-stage medicines in the iron deficiency, nephrology and cardio-renal therapeutic areas. We are committed to delivering innovative therapies that will change treatment paradigms and improve patients’ lives.
All product names and trademarks are the property of their respective owners, which are in no way associated or affiliated with Relypsa, Inc.